| ER/PR + HER2- | ER/PR + HER2+ | HER2 type | Basal-like | Unclassified | |||||
---|---|---|---|---|---|---|---|---|---|---|
n | OR | n | OR | n | OR | n | OR | n | OR | |
EGFR | ||||||||||
Positive | 16 | 1.0 (Ref) | 5 | 2.77 (0.69, 9.44) | 19 | 9.64 (3.76, 20.53) | 34 | 104.55 (41.51, 856.77) | 0 | 0.00 (0.00, 2.75) |
Negative | 283 | Â | 35 | Â | 39 | Â | 3 | Â | 28 | Â |
PTEN | ||||||||||
Reduced | 156 | 1.0 (Ref) | 18 | 0.75 (0.35, 1.55) | 16 | 0.31(0.16, 0.63) | 28 | 2.57 (1.11, 6.37) | 16 | 1.31 (0.55, 3.15) |
Normal | 140 | Â | 23 | Â | 42 | Â | 9 | Â | 12 | Â |
Bcl- 2 | ||||||||||
Positive | 249 | 1.0 (Ref) | 27 | 0.41 (0.19, 0.99) | 7 | 0.02 (0.01, 0.07) | 6 | 0.04 (0.01, 0.12) | 14 | 0.20 (0.08, 0.49) |
Negative | 51 | Â | 13 | Â | 51 | Â | 31 | Â | 14 | Â |
c -Kit | ||||||||||
Positive | 15 | 1.0 (Ref) | 0 | 0.00 (0.00, 2.16) | 7 | 2.70 (0.84, 7.48) | 10 | 7.50 (2.60, 20.96) | 1 | 0.73 (0.02, 5.29) |
Negative | 287 | Â | 41 | Â | 51 | Â | 27 | Â | 27 | Â |
c- Met | ||||||||||
Positive | 203 | 1.0 (Ref) | 34 | 1.98 (0.79, 5.54) | 47 | 2.63 (1.14, 6.70) | 28 | 1.43 (0.61, 3.60) | 16 | 0.58 (0.23, 1.44) |
Negative | 89 | Â | 7 | Â | 8 | Â | 9 | Â | 11 | Â |
Survivin | ||||||||||
Positive | 240 | 1.0 (Ref) | 34 | 1.32 (0.50, 4.20) | 56 | 7.54 (1.74, 61.08) | 30 | 1.25 (0.05, 3.52) | 23 | 1.41 (0.46, 4.91) |
Negative | 62 | Â | 6 | Â | 2 | Â | 7 | Â | 5 | Â |